Wall Street Zen Downgrades Synaptogenix (NASDAQ:TAOX) to Sell

Synaptogenix (NASDAQ:TAOX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Synaptogenix in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Synaptogenix Stock Performance

Shares of Synaptogenix stock opened at $4.27 on Friday. The company has a 50-day moving average price of $5.38. Synaptogenix has a fifty-two week low of $1.84 and a fifty-two week high of $11.98. The company has a market capitalization of $31.81 million, a price-to-earnings ratio of -0.21 and a beta of 1.98.

Synaptogenix (NASDAQ:TAOX) last issued its earnings results on Friday, November 14th. The company reported ($1.56) EPS for the quarter. The firm had revenue of $2.41 million during the quarter.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.